These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38042256)

  • 21. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
    Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
    Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CD34
    Pedraza A; Salas MQ; Rodríguez-Lobato LG; Charry P; Suárez-Lledo M; Martínez-Cibrian N; Doménech A; Solano MT; Arcarons J; de Llobet N; Rosiñol L; Gutiérrez-García G; Avilés FF; Urbano-Ispízua Á; Rovira M; Martínez C
    Transplant Cell Ther; 2023 Mar; 29(3):181.e1-181.e10. PubMed ID: 36526259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation.
    Wu L; Zhou M; Li Y; Chen X; Mo W; Wang C; Xu S; Zhou W; Deng T; Zhou R; Pan S; Wang S; Zhang Y
    Transplant Cell Ther; 2023 Jul; 29(7):463.e1-463.e7. PubMed ID: 37098408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
    Jurdi NE; Hoover A; O'Leary D; Cao Q; Gupta A; Ebens C; Maakaron JE; Betts BC; Rashidi A; Juckett MB; Lund T; Bachanova V; MacMillan ML; Miller JS; Orchard PJ; Wagner JE; Vercellotti G; Weisdorf DJ; Dusenbery K; Terezakis S; Holtan SG
    Transplant Cell Ther; 2023 Sep; 29(9):576.e1-576.e5. PubMed ID: 37311510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.
    Shouman MT; Mansour OM; El Gammal MM; Abdel-Fattah RM; Samra MA; Elhaddad AM; Maher MA; Mahmoud HK
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):379-387. PubMed ID: 37363983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
    Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
    Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
    Maurer K; Ho VT; Inyang E; Cutler C; Koreth J; Shapiro RM; Gooptu M; Romee R; Nikiforow S; Antin JH; Wu CJ; Ritz J; Soiffer RJ; Kim HT
    Blood Adv; 2023 Aug; 7(15):3903-3915. PubMed ID: 37156098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
    Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
    Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
    Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
    Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
    Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
    Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ
    J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
    Brissot E; Labopin M; Labussière H; Fossard G; Chevallier P; Guillaume T; Yakoub-Agha I; Srour M; Bulabois CE; Huynh A; Chantepie S; Menard AL; Rubio MT; Ceballos P; Dulery R; Furst S; Malard F; Blaise D; Mohty M
    Blood Cancer J; 2024 Feb; 14(1):31. PubMed ID: 38374026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
    García-Cadenas I; Redondo S; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Oñate G; López J; Caballero AC; Miqueleiz S; Arguello-Tomas M; Briones J; Sierra J; Martino R
    Transplant Cell Ther; 2023 Jul; 29(7):473.e1-473.e6. PubMed ID: 37086849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts.
    Arcuri LJ; Hamerschlak N; Rocha V; Bonfim C; Kerbauy MN
    Transplant Cell Ther; 2021 Sep; 27(9):782.e1-782.e7. PubMed ID: 34146733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
    Saliba RM; Alousi AM; Pidala J; Arora M; Spellman SR; Hemmer MT; Wang T; Abboud C; Ahmed S; Antin JH; Beitinjaneh A; Buchbinder D; Byrne M; Cahn JY; Choe H; Hanna R; Hematti P; Kamble RT; Kitko CL; Laughlin M; Lekakis L; MacMillan ML; Martino R; Mehta PA; Nishihori T; Patel SS; Perales MA; Rangarajan HG; Ringdén O; Rosenthal J; Savani BN; Schultz KR; Seo S; Teshima T; van der Poel M; Verdonck LF; Weisdorf D; Wirk B; Yared JA; Schriber J; Champlin RE; Ciurea SO
    Transplant Cell Ther; 2022 Oct; 28(10):681-693. PubMed ID: 35853610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant.
    Bourgeois AL; Jullien M; Garnier A; Peterlin P; Béné MC; Guillaume T; Chevallier P
    Clin Transl Med; 2023 Apr; 13(4):e1242. PubMed ID: 37140099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
    Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.